TY - JOUR
T1 - Overexpression of parathyroid hormone-related protein inhibits pancreatic β-cell death in vivo and in vitro
AU - Cebrian, Ana
AU - García-Ocaña, Adolfo
AU - Takane, Karen K.
AU - Sipula, Darinka
AU - Stewart, Andrew F.
AU - Vasavada, Rupangi C.
PY - 2002/10/1
Y1 - 2002/10/1
N2 - Pancreatic β-cell survival is critical in the setting of diabetes as well as in islet transplantation. Transgenic mice overexpressing parathyroid hormone-related protein (PTHrP) targeted to β-cells using the rat insulin II promoter (RIP) display hyperinsulinemia, hypoglycemia, and islet hyperplasia, without a concomitant increase in β-cell proliferation rate or enlargement of individual β-cell size. Thus, the mechanism for increased β-cell mass is unknown. In this study, we demonstrated that β-cells of transgenic mice are resistant to the cytotoxic effects of streptozotocin (STZ) in vivo, as documented by a sixfold reduction in the rate of STZ-induced β-cell death in RIP-PTHrP mice relative to their normal siblings. The reduced cell death in transgenic mice is due neither to their increased islet mass nor to a decrease in their sensing of STZ, but rather results from PTHrP-induced resistance to β-cell death. This is also demonstrated in vitro by markedly reduced cell death rates observed in β-cells of transgenic mice compared with normal mice when cultured in the absence of serum and glucose or in the presence of STZ. Finally, we demonstrated that NH2-terminal PTHrP inhibits β-cell death. These findings support the concept that PTHrP overexpression increases islet mass in transgenic mice through inhibition of β-cell death.
AB - Pancreatic β-cell survival is critical in the setting of diabetes as well as in islet transplantation. Transgenic mice overexpressing parathyroid hormone-related protein (PTHrP) targeted to β-cells using the rat insulin II promoter (RIP) display hyperinsulinemia, hypoglycemia, and islet hyperplasia, without a concomitant increase in β-cell proliferation rate or enlargement of individual β-cell size. Thus, the mechanism for increased β-cell mass is unknown. In this study, we demonstrated that β-cells of transgenic mice are resistant to the cytotoxic effects of streptozotocin (STZ) in vivo, as documented by a sixfold reduction in the rate of STZ-induced β-cell death in RIP-PTHrP mice relative to their normal siblings. The reduced cell death in transgenic mice is due neither to their increased islet mass nor to a decrease in their sensing of STZ, but rather results from PTHrP-induced resistance to β-cell death. This is also demonstrated in vitro by markedly reduced cell death rates observed in β-cells of transgenic mice compared with normal mice when cultured in the absence of serum and glucose or in the presence of STZ. Finally, we demonstrated that NH2-terminal PTHrP inhibits β-cell death. These findings support the concept that PTHrP overexpression increases islet mass in transgenic mice through inhibition of β-cell death.
UR - http://www.scopus.com/inward/record.url?scp=0036789242&partnerID=8YFLogxK
U2 - 10.2337/diabetes.51.10.3003
DO - 10.2337/diabetes.51.10.3003
M3 - Article
C2 - 12351440
AN - SCOPUS:0036789242
SN - 0012-1797
VL - 51
SP - 3003
EP - 3013
JO - Diabetes
JF - Diabetes
IS - 10
ER -